Recurrent Islet Cell Carcinoma Terminated Phase 2 Trials for Romidepsin (DB06176)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00084461Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTreatment